|
Oct 4
|
Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last?
|
|
Oct 3
|
Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
|
|
Sep 30
|
Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B
|
|
Sep 4
|
Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference
|
|
Sep 3
|
Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal
|
|
Aug 28
|
Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade
|
|
Jul 29
|
Precision BioSciences to Report Second Quarter Results on August 1, 2024
|
|
Jun 20
|
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
|
|
May 13
|
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 8
|
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
|
|
May 7
|
Precision BioSciences to Report First Quarter Results on May 13, 2024
|
|
May 7
|
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
|
|
May 1
|
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
|
|
Apr 17
|
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
|
|
Apr 16
|
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
|
|
Apr 11
|
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?
|
|
Apr 2
|
Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know
|
|
Apr 2
|
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
|
|
Mar 27
|
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 27
|
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
|